Save on Oxbryta ODT with Coupons, Discounts & Savings Programs

Oxbryta ODT is the brand name for voxelotor and is available as an orally disintegrating tablet.

Oxbryta ODT is available as a 300 mg orally disintegrating tablet.

Oxbryta ODT is a hemoglobin S polymerization inhibitor and is used to treat sickle cell disease in people 4 years and older.

Oxbryta ODT works by attaching to your hemoglobins. This prevents them from clumping up, which in turn, prevents your RBCs from sickling.

Oxbryta ODT is available as 2 different tablet strengths, 300 mg and 500 mg. The 300 mg tablets for suspension are round shaped and are only to be used to make a suspension taken by mouth. The 500 mg tablets are oval shaped and must be swallowed whole.

• Adults and children 12 years and older: The typical dose is 1,500 mg by mouth once per day

Children 4 to 11 years old: The typical dose is based on your child’s weight:

• 88 lbs or more: 1,500 mg by mouth once per day
• 44 to 88 lbs: 900 mg by mouth once per day
• 22 to 44 lbs: 600 mg by mouth once per day

Your dose might differ if you have severe liver problems or if you’re taking medications that interact with Oxbryta (voxelotor).

Oxbryta ODT is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Oxbryta ODT:

• Vomiting
• Headache
• Diarrhea
• Stomach pain
• Nausea
• Fever
• Rash

Serious side effects are rare with Oxbryta ODT. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic reaction: rash, trouble breathing, swelling of lips, tongue, or face

The following medications may interact with Oxbryta ODT:

• Sensitive CYP3A4 Substrates: Avoid coadministration of sensitive
• CYP3A4 substrates with a narrow therapeutic index.
• Strong or moderate CYP3A4 Inducers: Avoid coadministration with strong or moderate CYP3A4 inducers. If unavoidable, increase the dose of OXBRYTA.

Pfizer

It is not known if Oxbryta ODT harms your unborn baby. NYVEPRIA should be given to a pregnant woman only if clearly needed. Talk to your doctor about stopping Oxbryta ODT if you are pregnant or planning to become pregnant.

• Voxelotor